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Purpose: Modern facilities for actively scanned ion beam radiotherapy allow in principle the use of
helium beams, which could present specific advantages, especially for pediatric tumors. In order to
assess the potential use of these beams for radiotherapy, i.e., to create realistic treatment plans, the
authors set up a dedicated 4He beam model, providing base data for their treatment planning system
TRiP98, and they have reported that in this work together with its physical and biological validations.
Methods: A semiempirical beam model for the physical depth dose deposition and the production of
nuclear fragments was developed and introduced in TRiP98. For the biological effect calculations the
last version of the local effect model was used. The model predictions were experimentally verified at
the HIT facility. The primary beam attenuation and the characteristics of secondary charged particles
at various depth in water were investigated using 4He ion beams of 200 MeV/u. The nuclear charge
of secondary fragments was identified using a ∆E/E telescope. 3D absorbed dose distributions were
measured with pin point ionization chambers and the biological dosimetry experiments were realized
irradiating a Chinese hamster ovary cells stack arranged in an extended target.
Results: The few experimental data available on basic physical processes are reproduced by their
beam model. The experimental verification of absorbed dose distributions in extended target volumes
yields an overall agreement, with a slight underestimation of the lateral spread. Cell survival along a
4 cm extended target is reproduced with remarkable accuracy.
Conclusions: The authors presented a simple simulation model for therapeutical 4He beams which
they introduced in TRiP98, and which is validated experimentally by means of physical and biological
dosimetries. Thus, it is now possible to perform detailed treatment planning studies with 4He beams,
either exclusively or in combination with other ion modalities. C 2016 Author(s). All article content,
except where otherwise noted, is licensed under a Creative Commons Attribution (CC BY) license
(http://creativecommons.org/licenses/by/4.0/). [http://dx.doi.org/10.1118/1.4944593]
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1. INTRODUCTION
Radiotherapy with heavy charged particles is an established
option for the treatment of certain kinds of tumors.Most heavy
charged particle treatments are nowadays performed with pro-
tons and carbon ions (Table I). There is, however, some room
for unconventional beams other than these two ions. Whereas
the usage of pions certainly is history, there is growing interest,
for example, in fast helium ion beams. To some extent, they fill
the gap between protons and carbon ions. From the physical
point of view, theymight be advantageous since they cause less
projectile fragmentation than carbon ions and less lateral beam
spread than protons (see Fig. 1). From the radiobiological point
of view, their Relative Biological Effectiveness (RBE) is closer
to protons, though not negligible, but certainly lower than that
of carbon ions. This might be beneficial in certain treatment
situations, for example, for pediatric patients.
Pioneeringworkwas performed at LBNL (Berkeley, USA),
with some 2000 patients treated with 4He using a passive
beam delivery.1 With the advent of therapy facilities like
HIT (Heidelberg, Germany),2 CNAO (Pavia, Italy),3 and
soonMedAustron (Wiener Neustadt, Austria),4 equipped with
active beam delivery systems and providing multiple ion
species from protons through oxygen, a revival of 4He ions
is not unrealistic. For this to happen, however, the relevant
physical and radiobiological characteristics of 4He ions
interacting with biological matter need to be investigated in a
similar fashion, as was done for carbon ions. To achieve this
goal, a beammodel for aTreatment PlanningSystem (TPS) has
to be created and verified, which is the intention of this paper.
It is outlined as follow: in material and methods we shortly
introduce our treatment planning system, TRiP98, we describe
the experimental equipment used for verification and report on
the newly developed pragmatic beam model for therapeutic
4He ions. In Sec. 3 we report dosimetric results for absorbed
dose as well as cell survival distributions. We conclude with a
short discussion.
2. MATERIALS AND METHODS
2.A. Treatment planning system
One of the first steps for extending the treatment of cancer
patients to novel ion modalities is the development of a
(a) (b)
F. 1. (a) Depth dose distributions, (b) lateral beam spread for various beam modalities.
T I. Patient numbers by Dec-2013 (Ref. 5).
Ion Past Current Site
Protons 105 743
C-ions 13 119
Pions 1100 LANL, PSI, TRIUMF
He-ions 2054 LBNL
Other ions 433 LBNL
TPS. The natural choice is the well established TRiP98,6–8
developed in-house for clinical use during the carbon ion
pilot project at GSI.9 It also served as a prototype for the
commercial Siemens SynGo PT planning system, which is
currently in use at various ion beam radiotherapy sites [HIT,
CNAO, Shanghai, MIT (Marburg, Germany)]. Since the end
of the pilot project, it is used for research purposes, available
also outside GSI under certain conditions. Its flexible, largely
table-driven design allows to import new base data sets such
as depth dose distributions, particle spectra, and RBE tables.
It is constantly developed and enhanced and thus is the ideal
tool to investigate new beam modalities and their specific
applications.10,11
2.B. Experimental setup
2.B.1. Irradiation system
All experiments were performed at the Quality Assurance
(QA) room at HIT. The horizontal beam line is equipped
with five monitor chambers (two for position and three for
intensity control) on its outlet. The treatment plans were
realized considering the HIT available pool of monoenergetic
pencil beams, with specific energies, intensities, and beam
spot sizes. For basic physics experiments, a beam of 4He at
200MeV/u was delivered by RF knockout extraction from the
synchrotron. A monoenergetic pencil beam with a spot size
of approximately 5 mm FWHM measured at the isocenter,
i.e., 1.05 m from the beam nozzle. The beam intensity was
1000 particles/s, which is much below clinical levels, but
necessary for typical single particle physics measurements.
Higher beam intensities will cause pile-up of particle signals in
the detector, will lead to excessive dead-time in the electronics
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F. 2. Experimental setup to measure beam attenuation and fragment
buildup.
and data acquisition system and ultimatelymight even damage
the BaF2 detector. For therapy conditions, the intensity ismuch
higher, up to 8.0×108 particles/s.
2.B.2. Setup for basic physics data
For studying the absorption of primary 4He ions as a
function of water depth, the setup shown in Fig. 2 was used.
Particles exiting the beam line were monitored and counted
with a 1 mm thick plastic scintillator placed downstream of
the exit window. The surviving 4He ions together with the
lighter fragments produced by nuclear fragmentation were
identified by a telescope system consisting of a 9 mm thick
plastic scintillatorwith hexagonal shape and a 14 cm longBaF2
detector of hexagonal shape with an inscribed circle radius of
4.5 cm placed behind the water target. The target consisted of
several polystyrene flasks (manufactured by COSTAR). The
outer dimensions of each flask were x = 11.9 cm, y = 20.0 cm,
and z = 4.26 cm, where x and y denote the lateral size
and height (both perpendicular to the beam axis), and z the
extension along the beam direction. The material traversed by
the beam particles was 3.8 cm water and 0.42 cm polystyrene
(entrance and exit wall) for each flask. The total water-
equivalent thickness of one flaskwas 4.229 cm.Weused 1, 2, 4,
5, and 6 flasks to measure the particle yield at water equivalent
depths of 4.2, 8.4, 16.8, 21, and 25.2 cm, respectively. The
water target central axis was aligned to the isocenter (See
Fig. 2). Charged particles emerging from the water target
were identified in a 2D scatter plot of energy loss versus
residual energy (∆E−E, Fig. 3) using a graphical window.12,13
The identification of particles with different charge number Z
and mass number A is not unambiguous. We estimate the
uncertainty of the measured yield to be 2% for the helium
isotopes and 9% for the hydrogen isotopes.
F. 3. Residual energy versus energy loss scatter plot for a 200 MeV/u 4He
beam on 17 cm of water.
F. 4. Two-dimensional arrangement of pin point chambers to measure ab-
sorbed dose distributions. Actually it is a projection of the three dimensional
configuration onto the (x, z) plane. The first and last two lines along z are
staggered, respectively, ±6 mm in y direction.
2.B.3. 3D dosimetry
Absorbed dose distributions in irradiation plans were
measured with a set of pin point chambers [Multidos, PTW
(Refs. 14 and 15)] in a conventional water phantom. The
arrangement comprises a set of 24 pin point ionization
chambers with a sensitive volume of 0.03 cm3 and a diameter
of 2.9 mm, as shown in the xz plane projection of Fig. 4. The
six rows along z are staggered on three different y levels (see
Ref. 14 for details). It can be moved in x-, y-, and z-direction
with a resolution of 0.1 mm, in order to collect more data
points for a given cut through the dose distribution.
2.B.4. Biological dosimetry
Cell survival distributions as a function of depth were
measured with the stack setup shown in Fig. 5.
The 5×10×16 cm3 PMMA holder, typically used in our
group for extended target volume irradiations (see Ref. 16
for details), allows to place polystyrene slices holding cell
monolayers in several slots, with a resolution of 5 mm along
the beam direction.We selected our standard cell line, Chinese
hamster ovary cells (CHO-K1). This particular cell line has
the advantages of easy handling, regular growth under difficult
conditions, good reproducibility of results, and an α/β ratio
comparable to several human tissues. Moreover, in our group,
CHO cells were used with many different ions, in particular,
carbon and protons,16 which facilitates comparisons with
previous data. For modeling purposes, other cell lines such
as V79 or Human Salivary Gland (HSG) are of course also
conceivable, because the validity of our radiobiological model
does not depend on a particular cell line. Fifty thousand CHO-
K1 cells were seeded in each of these 25 cm2 slices 24 h
before irradiation, and after irradiation they were trypsinized,
measuring cell survival according to the standard procedure.17
In order to increase the resolution in depth, and to obtain
a denser measurement grid especially in the region of the
highest dose gradient, two different setups were used. In one
of the two configurations (setup B), an additional layer of
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(a) (b)
F. 5. Experimental device used for one dimensional cell survival distribution measurement. On the left, the overall sketch of the device comprising several
slots for slices supporting cell layers; on the right, top view showing the specific sampling points (slots) which were chosen with respect to the planned target
volume and the two different setups used for increasing the depth resolution. WEQ denotes “Water EQuivalent.”
material (polystyrene) was added [see Fig. 5(b)], to shift all
the sampling points by 2.51 mm. The slight modification in
the water equivalent path length induced by each slice of
polystyrene (factor 1.04) was accounted for. Clonogenic cell
survival assay was performed. For each setup, the results were
collected from two independent experiments, as average and
standard deviation (error bars). Considering the variability of
the cell’s radiosensitivity (Subsection 3.C), we thought that,
having only two measurements, the standard deviation would
be more appropriate as a confidence interval. In each of the
experiments the survival was determined by three technical
replicates used for seeding, i.e., different replicated samples
of colonies were seeded and counted from the same irradiated
sample.
2.C. Physical beam model
Previous approaches used a pencil beam model of the
absorbed dose distribution to describe therapeutic 4He ion
beams.18 While this is the natural first step, it is not enough to
enable realistic treatment planning including radiobiological
effects, which is the state of-the-art for our TRiP98 TPS.
Establishing a physical beam model for our purposes
requires a set of basic information: energy loss tables (dE/dx)
for all participating primary and secondary ions, nuclear
reaction cross sections describing the loss of primary beam
particles, and fragmentation cross sections to calculate the
build up of secondary ions as the beam traverses matter.
Electromagnetic energy losses are calculated according
to Salamon.19 Assuming an average ionization potential of
77 eV, the agreement between calculated and measured Bragg
peak positions is within 0.5 mm for a variety of light ions at
therapeutic energies. This choice of the ionization potential
is indeed somewhat arbitrary. To the best of our knowledge
no ab initio calculation with sufficient accuracy exists for
this quantity. A sensitivity analysis reveals that the position
of the Bragg peak shifts by ≈0.3 mm for 1 eV shift of the
ionization potential. The pragmatic way to deal with this
situation is to fine tune this value according to the measured
Bragg peak position for a few selected beam energies. The
description of nuclear interactions is more difficult, since only
few experimental data are available for hydrogen and oxygen
targets and classical reaction models like Silberberg and
Tsao20 are less suited for collision systems in the therapeutical
range. A semiempirical model at least partially suited for our
purposes was proposed by Cucinotta et al.21 It assumes two-
body dissociation of light ions to predict fragmentation cross
sections. Since our main target is water (as a substitute for soft
(a) (b)
F. 6. Total reaction cross sections for 4He on p, 12C, and 16O targets as a function of the energy. Symbols are experimental data taken from Refs. 25 and 26
(p), Refs. 27–31 (12C), and Refs. 27, 30, and 31 (16O).
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T II. Breakup channels of 4He on p (Ref. 32).
Reaction Threshold (MeV)
4He+p→2H+ 3He (pickup) 22.94
→p+ p+3H 24.77
→p+n+3He 25.72
→p+2H+2H (pickup) 29.81
→p+ p+n+2H 32.59
→p+ p+ p+n+n 35.37
tissue), we have to treat collisions of 4He with protons as well
as with oxygen nuclei.
2.C.1. Total reaction cross sections
Total reaction cross sections are conveniently described by
variants of the Bradt–Peters formula.22 We implemented the
algorithms given by Tripathi23 and by Sihver,24 respectively,
and verified them against the few experimental data available
in the literature. Figure 6 shows the comparison of calculated
and measured total reaction cross sections. For proton targets,
the Tripathi formula gives considerably better agreement,
within the error bars. In addition to 16O, we chose 12C as
a representative for heavier targets. For these targets, the
difference between the two algorithms is less pronounced at
lower energies, but still the Tripathi curves are closer to the
experimental data. Thus,we prefer the Tripathi formula for 16O
and 12C as well. One should note, however, the relatively large
spread of the experimental values, which leaves some room
for the modification of cross section formulae. Furthermore,
one should note the large gap between 100 and 400 MeV/u,
which unfortunately coincides with the range of therapeutical
interest, i.e., 50–200 MeV/u, as well as with the “dip” in the
calculated cross section curve.
2.C.2. Fragmentation cross sections
Fortunately only a limited number of reaction channels
exists for 4He collisions with hydrogen. They are summarized
in Table II, together with their threshold energies.
To calculate the cross sections for fragments created in the
breakup channels we follow the propositions in Ref. 21 and
obtain the phenomenological formulae
σ3He = 47.5
(
2
1+e(Tth−T )/9
−1
) (
1−
0.3
1+8e−T /39
)3
×
(
1+0.70

T/520
)
e−(T−780)/4300, (1)
σ3H = 8.83
(
2
1+e(Tth−T )/7.3
−1
) (
1−
0.3
1+7e−T /73
)3
×
(
1+6.54

T/550
)
e−(T−750)/4383, (2)
σ2H= 17
(
2
1+e(Tth−T )/12
−1
) (
1+
0.21(T/145−1)
1+e(145−T )/6
)
e−T /3000,
(3)
where T is the projectile energy (in MeV/u) and Tth the
respective threshold energy from Table II.
The breakup cross sections are completed by adding the
“pickup” contributions for 2H and 3He:
σPickup= 48e
−(T−Tth)
1.7/1350. (4)
For the remaining cross section for 1H production nomodel
description exists, thus we estimate it from the already known
cross sections as34
σ1H =
3
5
(
σR−σPickup,3He+σ3H−0.5σ3He
− 0.5σPickup,2H−
1
3
σ2H
)
(5)
by balancing the reaction channels in Table II.
We compare the obtained cross sections with experimental
data in Fig. 7. The agreement is acceptable, considering the
data sparsity and their relatively large uncertainties.
For heavier targets, a scaling procedure was adopted using
empirical factors roughly proportional to the target nucleus
radius, i.e., ∝A1/3.21,35 The scaling factors are collected in
Table III.
Experimental fragmentation cross sections for oxygen
targets were not available, so we verified against experimental
data from 12C targets (Fig. 8). The agreement is acceptable
considering the few data points and their error bars.
2.D. Biological effect calculation
Our TPS calculates radiobiological effects by separating
variable quantities like field directions and particle fluence
maps from invariant base data such as the linear–quadratic
(a) (b) (c)
F. 7. Fragmentation cross sections for 2H, 3H, and 3He in 4He-p collisions. Symbols are experimental data taken from Ref. 33.
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T III. Scaling factors for σF in
4He–carbon (oxygen) collisions.
Cross section Scaling factor
σ1H A
0.46
T
σ2H A
0.4
T
, A
1/3
T
(pickup)
σ3H A
0.31
T
σ3He A
0.31
T
, A
1/3
T
(pickup)
(LQ) model parameters for single particle traversal, αz, βz.
The algorithms how to combine these in order to obtain
macroscopic quantities such as cell survival, lethal effect, and
the associated RBE are described elsewhere.37 The single
particle αz, βz tables are externally supplied by means
of the Local Effect Model (LEM) in version IV.16 This
version is based on a fine tuned partitioning between isolated
and clustered DNA double strand breaks caused by the
local dose deposition. As a consequence, it describes more
adequately the different effectiveness of low- and high-LET
radiations, respectively. So, unlike its predecessors, LEM IV is
particularly suited to describe radiobiological effects of lower
LET radiation such as protons and helium ions.
3. RESULTS
3.A. Transport calculation
Using the cross sections calculated as described in the
previous section, we can perform transport calculations as
described elsewhere.6,7 In a first test, we compare with
measurements of the primary beam attenuation and the build
up of projectile fragments as the beam traverses thicker slabs
of water (Fig. 9). These observables can simply be obtained
numerically using the nuclear interaction cross sections and
the electromagnetic energy loss discussed earlier, there is no
need to involve intransparent Monte Carlo codes. Within the
experimental uncertainties, we find good agreement for
the primary beam and 3He. In particular the agreement of
the primary beam attenuation up to 8 cm, corresponding to
beam energies between 200 and 160 MeV/u, confirms the
total reaction cross sections assumed in Fig. 6. Hydrogen
isotopes, in particular protons, however, are overestimated by
the calculation by a factor of roughly two. These discrepancies
remain, although experimental uncertainties such as limited
angular acceptance, energy thresholds in the detectors and self
pile-up of protons are accounted for. This is not too surprising,
since the hydrogen isotope production especially for oxygen
targets is only estimated by means of the semiempirical
factors in Table III. These factors are only weakly confirmed
for carbon targets, Fig. 8, and we have no independent
confirmation for oxygen targets. Of course one could start to
modify Table III for oxygen targets to obtain better agreement
with the measurements, but we decided not to do so. On the
other hand, the hydrogen isotopes do not contribute much
to the absorbed dose or cell survival. In order to estimate
the influence of suboptimal hydrogen cross sections, we
performed a sensitivity analysis of the resulting cell survival
calculations, presented in Subsection 3.C.
Depth dose profiles (planar integrated dose distributions)
serve as a further cross check for the model validity. Unfor-
tunately, at the time of the model development only legacy
data from the LBNL radiotherapy project were available for
comparison. Experimental details were not available, so some
plausible assumptions had to be made. Figure 10 shows our
model calculations for two energies of therapeutical interest
in comparison with experimental data.38 The experimental
data were shifted by 9.6 mm to match the predicted position
of the Bragg peak(s). We consider this to be justified since
the properties of the beam delivery (e.g., boli in the beam
path) are not known and calculations of the Bragg peak
position are believed to be reliable. Unfortunately only few
data points beyond the peak are available (at 150 MeV/u) to
verify the fragmentation tail contribution, but the agreement
is acceptable.
3.B. Absorbed dose verification
The physical beam model is verified by a set of absorbed
dose measurements in depth as well as in lateral direction.
For extended target volumes the absorbed dose distribution is
calculated using established pencil beam algorithms6 which
include multiple Coulomb scattering, the angular distribution
(a) (b)
F. 8. Fragmentation cross sections for 1H, 2H and 3H, 3He in 4He-12C collisions. Symbols are experimental data taken from Ref. 35 (a) and Refs. 35 and
36 (b).
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(a) (b)
F. 9. Attenuation and fragment build up of a 4He beam of 200 MeV/u as a function of depth in water. Symbols represent measurements with the setup
described in Subsection 2.B.2, while the curves are our transport calculations.
of nuclear fragments, and the divergence of the beam at depths
far off the assumed isocenter. Figure 11 reports results for a
30×50 mm2 target volume covering a depth of 40 mm. Inset
(a) shows depth dose distributions taken along a cut traversing
the target volume through the isocenter. The agreement with
the prediction (blue curve) is about 3% in the target volume,
about 9% at the distal edge, and about 5% in the entrance
channel.
In Fig. 11(a) we have added another set of absorbed dose
measurements, corresponding directly to the cell survival
measurement shown in Fig. 12 (red symbols). The target
volume was slightly different, but comparable, whereas the
planned dose level in the target was 4 Gy (scaled down to
1 Gy in Fig. 11). The deviation at the distal edge of the target
volume is much less than in the previous case. The two sets
of measurements differ by ≈2%, which might serve as an
indication of the intrinsic uncertainty of the experiment.
Figure 11(b) shows lateral dose distributions taken at 15.8
and 68mm depth, respectively. The overall agreement is good,
with an underestimation of the central dose corresponding to
the deviations seen in 11(a). There is a noticeable deviation
F. 10. Depth dose profiles for 4He beams of two energies. Symbols are
experimental data reproduced from J. Lyman and J. Howard, “Dosimetry and
instrumentation for helium and heavy ions,” Int. J. Radiat. Oncol. Biol. Phys.
3, 81–85 (1977).
at the edges of the target volume, which also needs further
investigation.
Since this is a first set of measurements, it is still under
investigation whether the observed deviations arise from
shortcomings of the applied beam model or the experimental
conditions, such as beam spot size, beam divergence, or
calibration of the scanning system.
3.C. Biological dose verification
Figure 12 presents the results of the biological verifica-
tion measurements, performed with the experimental setup
described in Sec. 2. A 60×100 mm2 target volume centered
at a depth of 82 mm was irradiated with a homogeneous
absorbed dose of 4 Gy, i.e., with a plan optimized on
uniform absorbed dose all along the target. The corresponding
nonhomogeneous survival distribution was forward calculated
using two different sets of αx and βx to characterize the
linear–quadratic X-ray survival curve used as the reference
radiation for LEM IV. One set, labeled “mean,” represents the
average of αx, βx values for the used cell line, taken over
the last five years (αx,βx = 0.171,0.02). The other set, labeled
“2014,” was specifically obtained during an X-ray calibration
measurement a few days before the 4He experiments (αx,βx
= 0.1,0.034).Within experimental error bars, both calculations
give good agreement with the experimental results. The two
calculations differ by approximately 8% in survival level,
demonstrating the natural time variation of radiosensitivity
for the CHO cell line used.
3.C.1. Sensitivity analysis with regard to absorbed
dose deviations
It is conceivable that the deviations between measured and
predicted absorbed dose, Fig. 12(a), in particular at the distal
edge, could affect the validity of the biological predictions.
We thus provide an additional depth survival profile based on
an absorbed dose distribution adapted to the measured data.
The difference to the nominal survival rate is between 5%
and 10% in the target region, but still within the error bars
of the experimental survival values. Hence one of the main
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F. 11. (a) Depth dose distributions for a target volume at 83 mm depth, covering a depth range of 40 mm (blue symbols) The open symbols correspond to
the plan used for the biological measurement shown in Fig. 12, scaled down by a factor 4. The solid curves are the respective TPS predictions. (b) Lateral dose
profiles taken at 15.8 and 68 mm depth, respectively. The solid curves are the TPS predictions.
conclusions, i.e., the steep rise of RBE toward the distal edge,
remains valid.
3.C.2. Sensitivity analysis with regard
to fragment contributions
Since the used nuclear fragmentation cross sections have a
rather large uncertainty we performed a sensitivity analysis in
order to estimate their influence on the depth survival profile,
Fig. 13(b). It turns out that their influence is vanishing in the
entrance channel as well as at the distal edge, as it should
be, since at these positions the primary beam dominates.
The largest effect arises from the 3He contribution in the
proximal and central part of the target volume. There, the
survival rate may change by 10% (e.g., from 0.32 to 0.35)
when 3He is excluded from the calculation. The hydrogen
isotopes play only a minor role, on the order of 5% altogether,
and the influence of protons [from the red to the blue curve in
Fig. 13(b)] is hardly visible.
3.C.3. Comparison with the literature data
We also looked for comparisons with the literature data,
in particular from the pioneering research at LBNL. This
is not straightforward given the historical time frame, and
the vastly different experimental setups. For human T-1 cells
irradiated with 70 Gy equivalent to 60Co in five fractions
an overall RBE of 1.3 for cell killing is reported for a
simulated tumor location (from 1.5 to 2.5 cm depth in
water).39 Another experiment reports RBE values of 1.2 ± 0.2
determined at the center of a target volume extending from
10.5 to 21 cm, irradiated with 5.5 Gy.40 These RBE values
are compatible with our findings, at least in the center of
the target volume. One should keep in mind, however, that
their experimental conditions are quite different from ours
as far as cell lines, dose per fraction, and simulated tumor
locations are concerned. Certainly the static RBE values used
at LBNLwere appropriate at their time. However, RBE values
depend on dose level, irradiation geometry, and tissue type.
With today’s 3D active scanning technique, it is mandatory
to assign an individual RBE value to each irradiated voxel.
Even if the rise of RBE at the distal edge would be less
pronounced, due to the absorbed dose deviations discussed
above, the assumption of a constant RBE is no longer
appropriate, since the measured depth survival values vary
by a factor of four. Moreover, a strong rise of RBE will also
influence the effective range at the distal edge of the target
volume.41
F. 12. Depth profiles for the biological verification, with the target volume centered at 82 mm depth, covering a depth range of 40 mm. (a) Calculated absorbed
dose, RBE-weighted dose, RBE and dose-averaged LET depth profile. The symbols represent absorbed dose measurements performed with the setup described
in Subsection 2.B.3 in a different run but with the same treatment plan. (b) Depth survival profile, symbols represent measurements with different setups, the
two curves are predictions by our TPS using different values of α and β of the reference radiation.
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F. 13. Sensitivity analysis of the survival profile for the “2014” case in Fig. 12(b). (a) With a dose profile adapted to the measured absorbed dose in Fig. 12(a).
(b) With respect to nuclear fragment contributions.
4. DISCUSSION AND CONCLUSIONS
The agreement between biological verification data and
TPS prediction shows that a pragmatic physical beam model
together with the radiobiological model can be used to provide
realistic 4He ion treatment plans. In particular, the well
reproduced strong variation of cell survival around 105 mm
depth, which usually is hard to catch, gives good confidence
in the overall accuracy of the chosen modeling.
Realistic treatment plans are mandatory for future compar-
isons between different ion beam modalities. Although
advantages and disadvantages might be estimated from simple
physical and radiobiological properties of the single ions, full
treatment plans under patient conditions often enough reduce
or modify the theoretical differences between the various ion
modalities. As it has been shown by Grün et al.,42 who used
our TPS to compare protons, 4He and 12C ions, respectively,
there is no unique choice for an optimal ion species. It largely
depends on patient specific parameters such as field configu-
ration, α and β values and even the prescribed dose level.
Extensive comparative planning studies, however, are
beyond the scope of this contribution and are left for future
research.
Other directions for future experimental investigation are
the necessity to clarify the deviations between absorbed dose
measurements and TPS predictions, as well as filling the cross
section data gap in the therapeutic region between 50 and
200 MeV/u.
Last but not least more patient-like biological verifica-
tion measurements are planned, covering survival distri-
butions in two dimensions as well as lateral survival
distributions.
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